Skip to main content

[DP-1111-02CT] A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

ITM Solucin GmbH

Start Date

April 21, 2022

End Date

July 21, 2026
 

Administered By

Duke Cancer Institute

Awarded By

ITM Solucin GmbH

Start Date

April 21, 2022

End Date

July 21, 2026